Gastroparesis is a disorder affecting people with both type 1 and type 2 diabetes in which the stomach takes too long to empty its contents (delayed gastric emptying).
Diabetic Gastroparesis (DGP) is a serious complication of diabetes that results in delayed gastric emptying with associated upper gastrointestinal symptoms in the absence of any mechanical obstruction.
- The total Diabetic Gastroparesis prevalent population in the 7MM is expected to rise to 17,859,995 in 2030.
- About 40% of patients with Type 1 Diabetes have Gastroparesis.
- Around 30% of Type 2 Diabetes Mellitus (DM) cases suffer from Diabetic Gastroparesis.
- The prevalence of both T1DM and T2DM associated Diabetic Gastroparesis was highest in the United States.
- Among the Diabetic Gastroparesis patients, females account for a higher number in comparison to males.
Nausea was the most common symptom and Abdominal Pain was the least common symptom associated with Diabetic Gastroparesis.
Scope of the Report
- The Diabetic Gastroparesis report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
- The Diabetic Gastroparesis Epidemiology Report and Model provide an overview of the risk factors and global trends of Diabetic Gastroparesis in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
- The report provides insight about the historical and forecasted patient pool of Diabetic Gastroparesis in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
- The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
- The report assesses the disease risk and burden and highlights the unmet needs of Diabetic Gastroparesis
- The report provides the segmentation of the Diabetic Gastroparesis epidemiology
1. Key Insights
2. Executive Summary of Diabetic Gastroparesis
3. Diabetic Gastroparesis: Disease Background and Overview
3.2. Sign and Symptoms
3.4. Risk Factors
4. Patient Journey
5. Epidemiology and Patient Population
5.1. Epidemiology Key Findings
5.2. Assumptions and Rationale: 7MM
5.3. Epidemiology Scenario: 7MM
5.3.1. Diabetic Gastroparesis Epidemiology Scenario in the 7MM (2017- 2030)
5.4. United States Epidemiology
5.4.1. Diabetic Gastroparesis Epidemiology Scenario in the United States (2017- 2030)
5.5. EU-5 Country-wise Epidemiology
5.5.1. Germany Epidemiology
188.8.131.52. Diabetic Gastroparesis Epidemiology Scenario in Germany (2017- 2030)
5.5.2. France Epidemiology
184.108.40.206. Diabetic Gastroparesis Epidemiology Scenario in France (2017- 2030)
5.5.3. Italy Epidemiology
220.127.116.11. Diabetic Gastroparesis Epidemiology Scenario in Italy (2017- 2030)
5.5.4. Spain Epidemiology
18.104.22.168. Diabetic Gastroparesis Epidemiology Scenario in Spain (2017- 2030)
5.5.5. United Kingdom Epidemiology
22.214.171.124. Diabetic Gastroparesis Epidemiology Scenario in the United Kingdom (2017-2030)
5.6. Japan Epidemiology
5.6.1. Diabetic Gastroparesis Epidemiology Scenario in Japan (2017- 2030)
6. Treatment Algorithm, Current Treatment, and Medical Practices
6.1. Diabetic Gastroparesis Treatment and Management
6.2. Diabetic Gastroparesis Treatment Algorithm
7. KOL Views
8. Unmet Needs
9.2. Report Methodology
10. DelveInsight Capabilities
12. About DelveInsight